Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
150
resultados
Última actualización
04/07/2025 [07:37:00]
Resumen de: US2025218598A1
Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.
Resumen de: WO2025137110A1
Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: AU2023401746A1
Techniques for performing application-layer security and communication over primary invitation channels arc disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: US2025205427A1
Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
Resumen de: US2025204816A1
An apparatus for monitoring glucose according to an embodiment of the present invention includes an input unit that obtains first biometric information including a plurality of data points measuring glucose-related information of a subject; a noise removal unit that removes noise information included in the first biometric information; a preprocessing unit that preprocesses the first biometric information from which the noise information is removed to generate second biometric information having a lower sampling rate than the first biometric information; a compensation unit that generates compensation data based on the second biometric information and generates a calibration algorithm based on the compensation data; and a glucose level acquisition unit that acquires a glucose level related to the second biometric information by reflecting the calibration algorithm and a set time delay.
Resumen de: US2025204813A1
Devices, systems, and methods herein relate to managing a chronic condition such as diabetes. These systems and methods may obtain patient data from a plurality of devices, integrate the data for analysis of trends that may be presented to the patient and/or health care professional along with an actionable suggestion. In some variations, a method may include the steps of receiving analyte data generated by an analyte measurement device and patient data generated by a patient measurement device. One or more data trends may be generated by analyzing the analyte data against the patient data using a computing device. The device settings of one or more of the analyte measurement device and the computing device may be modified in response to one or more of the data trends.
Resumen de: US2025204814A1
A stretchable, conducting, and redox-active hydrogel with an interpenetrating double-network structure is provided. This structure is formed by infiltrating a brittle pure-gel conducting hydrogel with a stretchable hydrogel. Ferrocene derivatives are immobilized on the chains of the stretchable hydrogel through covalent bonds, and glucose oxidases are crosslinked to the stretchable hydrogel using a room-temperature crosslinker.
Resumen de: WO2025134124A1
Embodiments of the disclosure generally relates to systems and methods for real time continuous monitoring of glucose. More specifically, the embodiments of the disclosure relate to a device for continuous glucose monitoring (COM), that includes subcutaneous electrochemical sensor, electronics, and algorithms to improve ease of manufacture, use, and more importantly, the welfare of people with diabetes.
Resumen de: US2025210156A1
Methods and system to provide glycemic control and therapy management based on monitored glucose data, and current and/or target HbA1C levels are provided.
Resumen de: US2025204815A1
The present disclosure discloses a photoacoustic diagnostic device. More specifically, the present invention relates to a photoacoustic diagnostic device that detects ultrasound waves generated by irradiating a biological surface with a laser to noninvasively determine blood sugar concentration, or the like in a biological body. According to an embodiment of the present invention, the photoacoustic diagnostic device is equipped with a membrane element manufactured by a micro electro mechanical system (MEMS) process, and instead of mounting an expensive FFT, or the like on a transducer for receiving an ultrasound wave signal radiated from a subject and detecting a resonance peak or using a spectrum analyzer, by detecting multiple resonance peaks through multiple transducers with different resonance frequencies and combining the resonance peaks to perform analysis on blood sugar, or the like, it is possible to provide analysis results with high accuracy that are easy to implement and low cost.
Resumen de: EP4574038A2
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Resumen de: EP4576110A2
Embodiments described herein relate to a glucose monitoring system having a glucose sensor positioned in contact with interstitial fluid in a body of a user. A transmitter unit is coupled to the glucose sensor and processes data indicative of a plurality of monitored glucose levels from the glucose sensor. A receiver unit receives the processed data from the transmitter unit. The receiver unit comprises a processor and a user interface having a touch-sensitive display to render a plurality of display screens, including a home screen and an alert screen. The home screen is divided into a plurality of simultaneously displayed panels, with a first panel displaying the plurality of monitored glucose levels, a second panel simultaneously displaying a current glucose level and a glucose trend indicator, and a third panel displays status information of a plurality of components of the system. When an alarm condition is detected, the display renders the alert screen in place of one of the first panel, the second panel, or the third panel. The alert screen displays information corresponding to the detected alarm condition. The display affects a further output corresponding to the detected condition in response to user actuation of a portion of the display.
Resumen de: EP4574039A1
An apparatus for monitoring glucose according to an embodiment of the present invention includes an input unit that obtains first biometric information including a plurality of data points measuring glucose-related information of a subject; a noise removal unit that removes noise information included in the first biometric information; a preprocessing unit that preprocesses the first biometric information from which the noise information is removed to generate second biometric information having a lower sampling rate than the first biometric information; a compensation unit that generates compensation data based on the second biometric information and generates a calibration algorithm based on the compensation data; and a glucose level acquisition unit that acquires a glucose level related to the second biometric information by reflecting the calibration algorithm and a set time delay.
Resumen de: EP4574023A1
A method for non-invasively estimating blood glucose for estimating a blood glucose value of a user by a computing device (400A, 400B, 2600). The method includes receiving a plurality of electrocardiogram (ECG) waveforms of the user, extracting at least two first ECG features from each of the plurality of ECG waveforms of the user, respectively determining a first feature peak position corresponding to each of the first ECG features, calculating at least one peak distance between the plurality of the first feature peak positions, and estimating the blood glucose value of the user based on the peak distance. The first ECG features are selected from the group consisting of a P-wave, a Q-wave, an R-wave, an S-wave, a T-wave, and a U-wave. Furthermore, a computing device (2600) for non-invasively estimating blood glucose, a device (2700) for non-invasively measuring ECG signal, and a non-transitory computer readable storage medium are utilized for the method.
Resumen de: US2025176870A1
A device for determining a glucose concentration in an anterior chamber of a user's eye includes a VCSEL which emits laser light, and an optical element for influencing the laser light and/or an emergent light. The VCSEL and the optical element are configured such that the laser light enters the anterior chamber of the eye. The emergent light from the anterior chamber penetrates into the VCSEL. The device further includes an analysis unit that analyses a resulting self-mixing interference within the VCSEL to determine the glucose concentration.
Resumen de: AU2025203909A1
A controller in an insulin delivery system for the delivery of insulin to a patient, the controller configured to control operation of an insulin delivery device, the controller comprising: a chipset for establishing communications with a glucose monitor and a smartphone; one or more processors; and computer memory storing instructions that, when executed by the one or more processors, cause the one or more processors to: establish, using the chipset, a first network connection with the glucose monitor; establish, using the chipset, a second network connection with the smartphone, the smartphone running a mobile application, wherein the mobile application is executed by the smartphone; receive, via the first network connection, patient data related to blood glucose levels from the glucose monitor; transmit, via the second network connection, the patient data related to blood glucose levels to the smartphone; and receive, from the smartphone via the second network connection, an instruction to administer an insulin dosage, wherein the instruction to administer the insulin dosage is initiated by the mobile application running on the smartphone, and wherein the insulin dosage is based at least in part on the patient data related to blood glucose levels transmitted to the smartphone; and transmit, to the smartphone via the second network connection, a communication verifying that the administration of the insulin dosage has been completed.
Resumen de: AU2025203882A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Resumen de: US2025194970A1
The present invention provides a diabetes biosensor including a porous polymer membrane; two sides of the porous polymer membrane are provided with impermeable membranes; the impermeable membrane on one side is provided with a first electrode, the impermeable membrane on the other side is provided with a second electrode. Specific glucose oxidase is immobilized on the first electrode. In the present invention, the porous polymer membrane has the feature of multiple pores to facilitate the penetration of water and other liquids, and the impermeable membranes on two sides of the porous polymer membrane have the feature of impermeable; the porous polymer membrane, the impermeable membranes, the first electrode, and the second electrode together constitute a sandwich sensor; glucose generates hydrogen peroxide under the action of glucose oxidase; after the hydrogen peroxide generates electron gain and loss on the electrode, an electric signal change is generated and detected by the biosensor; and the biosensor can rapidly measure the blood glucose concentration. In addition, the biosensor can be used as a device for storing drugs, which facilitates the use of the biosensor to inject insulin into a patient with a high blood glucose concentration to control the blood glucose level.
Resumen de: US2025195002A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: US2025195755A1
A device for delivering medicament to a user is disclosed. The device is configured to be mounted to the user. The device comprises a baseplate including: an inlet opening and outlet opening to align with an inlet opening and outlet opening of a micropump, respectively; a first port for fluid in fluid communication with a catheter; and a first fluid channel to enable fluid communication between the first port and the outlet opening of the micropump; and a housing configured to engage the baseplate to form an interior therein, the interior including a first internal region that is sealed from fluid ingress and a second internal region that is not sealed from fluid ingress, wherein the inlet opening of the baseplate, the outlet opening of the baseplate and the first port are within the first internal region.
Resumen de: US2025195753A1
A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.
Resumen de: US2025195761A1
Systems and methods are provided for sending a software update to an insulin pump and/or user device used with the insulin pump and selectively enabling and disabling certain functionality (e.g., operations, tasks, functions, and/or features) enabled by the software update and/or settings adjusted by the software update. The software update may be in the form of a software package that is sent from a remote device to all insulin pumps or user devices on an insulin pump network. While all devices may receive the same software update it may be desirable to restrict certain functionality and/or settings for some insulin pumps and/or user devices. The insulin pump, user device associated with the insulin pump, and/or remote device in communication with the user device, may determine whether the functionality in the software update should be disabled or otherwise not enabled for a certain insulin pump and/or user device.
Resumen de: US2025195000A1
A wearable smart insole for a user having foot having a planter arch and a medial plantar artery (MPA) along the plantar arch is provided. The insole has at least one optical sensor disposed in the insole along the MPA, a power handling circuit, an energy storage module operatively coupled with the power handing circuit to provide power to the optical sensor. The optical sensor is disposed along the MPA in the insole and provides a signal for obtaining heart rate data, blood oxygen saturation data and blood glucose measurements. Two optical sensors may be provided along the MPA to provide signals for calculating blood pressure. A third optical sensor may be provided along the lateral plantar artery to provide signals to detect diabetes or arterial disease.
Resumen de: US2025195781A1
Disclosed are systems and methods for a computerized framework that electronically manages and controls a patient's therapy for proper administration of diabetic treatment. The framework includes a disposable pen injector that has integrated therein dose logging capabilities (e.g., a NFC circuit) for controlling the administration of the prescribed therapy. Electronic communications between the disposable pen injector and a therapy control application executing on a patient's device can effectuate accurate and efficient administration of prescribed therapy. The pen can communicate information to the patient's device, and the application executing thereon, that includes dosage information related to availability left in the pen, timing of doses, and the like. In a related manner, the application can compile dosage planning information that can dictate types of doses, amounts of doses, timing of doses, and the like, to ensure that the patient is complying with a prescribed diabetic prescription.
Nº publicación: US2025197515A1 19/06/2025
Solicitante:
REGENERON PHARMACEUTICALS INC [US]
Regeneron Pharmaceuticals, Inc
Resumen de: US2025197515A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
BOPI
Sede Electrónica
